TRPC5 and breast cancer: In adriamycin-resistant breast cancer cells MCF-7/ADM, adriamycin treatment increased TRPC5 expression, leading to the activation of the calmodulin-dependent signaling pathway (CaMKII/AMPKA/mTOR) and chemotherapy resistance (Zhang et al., 2017).